How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,301 results for

HIPAA

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

201. Telestroke for Comprehensive Stroke Care in Acute Stroke Ready Hospitals

ischemic stroke patients admitted to the participating ASRH after implementation of an inpatient telestroke service. Other: Telestroke Telestroke is an audiovisual communication network that allows for coordination of stroke care from a distant 'hub' site (the telestroke provider location) to an originating 'spoke' site (patient location) in a HIPAA compliant fashion. In TELECAST, inpatient telestroke rounding will be used to oversee the urgent diagnostic stroke evaluation, secondary stroke prevention

2018 Clinical Trials

202. REcycled CartiLage Auto/Allo IMplantation

and assessments Can provide written informed consent and complete HIPAA documentation after the nature of the study is fully explained and prior to any study-related procedure 1.2 Exclusion Criteria To be eligible for inclusion in this study, the subjects must not meet any of the following criteria: Pregnant or nursing, or planning on becoming pregnant during the study period Congenital or acquired malformation of the target knee resulting in significant deformity or leading to problems with the study

2018 Clinical Trials

203. An Evaluation of Changes in Psychological Health to a Yoga Program for Medical Residents

Khalsa, PhD, Assistant Professor of Medicine, Brigham and Women's Hospital ClinicalTrials.gov Identifier: Other Study ID Numbers: 2017P002372 First Posted: September 27, 2018 Last Update Posted: March 20, 2019 Last Verified: March 2019 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Undecided Plan Description: Kripalu will potentially be receiving data, analyzing data, and publishing. The data will be HIPAA de-identified. A research agreement between Kripalu and Partners

2018 Clinical Trials

204. The Navigator Trial

PDMP manages a database that contains information on all prescriptions for schedule II-IV substances filled in the state. The database is updated daily; all pharmacies are required to report prescriptions within 48-hours of the fill date. All records will be linked deterministically to participant data using identifiable information (e.g., name, social security number) within the Stronghold computing environment, a HIPAA-compliant server maintained by the team at Brown University. The proportion

2018 Clinical Trials

205. Prospective Elimination Of Distal Coronary Sinus-Left Atrial Connections for Atrial Fibrillation Ablation Trial

Verified: August 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Yes Plan Description: Information about study subjects will be kept confidential and managed according to the requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Those regulations require a signed subject authorization informing the subject of the following: What protected health information (PHI) will be collected from subjects in this study Who will have access

2018 Clinical Trials

206. Spectroscopic Magnetic Resonance Imaging of Glioma

of Excellence for HIPAA Data intended for storing, sharing and accessing sensitive and private-highly restricted files. Supporting Materials: Study Protocol Statistical Analysis Plan (SAP) Clinical Study Report (CSR) Analytic Code Time Frame: 2 years Access Criteria: The link to the data will be made available upon request Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH

2018 Clinical Trials

207. Riluzole Oral Soluble Film Swallowing Safety in Amyotrophic Lateral Sclerosis

with a diagnosis of probable or definite ALS in accordance with the Revisited El-Escorial Criteria (Cedarbaum, 1999) Subjects must be currently on an oral diet and able to take foods and liquids by mouth equivalent to a score of 3 or above on the Functional Oral Intake Scale (Crary, 2005). Subjects with no known allergy to barium, riluzole or inactive ingredients* in ROSF Subjects or subject's legally authorized representative must be willing and able to give informed consent/assent and HIPAA authorization

2018 Clinical Trials

208. NR in Chemo-induced Peripheral Neuropathy

a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 80 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Be able to give written informed consent and HIPAA authorization Be 18 to 80 years old Have been diagnosed with stage IV breast cancer of any type

2018 Clinical Trials

209. DPCP for the Treatment of Alopecia Areata

Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Subject has clinical diagnosis of extensive alopecia areata (76%-99% involvement as determined by SALT score, Appendix B, Part I). Written informed consent and HIPAA authorization have been obtained. Subject is > 18 to years of age. Female subjects of childbearing potential have a negative pregnancy test and agree to use an acceptable, highly effective method of birth control (i.e., failure rate of less than 1% per year

2018 Clinical Trials

210. Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria for the Study: Unless otherwise noted, subjects must meet all of the following criteria to participate in all stages of this study: Written informed consent and HIPAA authorization for release of personal health information. Adults ≥18 years of age. Histologically confirmed B-cell NHL, including the following types defined by WHO 2016: Aggressive Lymphomas: DLBCL not otherwise specified (NOS) T cell/histiocyte

2018 Clinical Trials

211. Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib

treatment: Has provided written informed consent as approved per local regulations with privacy language in accordance with national regulations (eg, Health Insurance Portability and Accountability Act [HIPAA] authorization for US sites) prior to any protocol-related procedures Is 18 years of age or the minimum legal adult age (whichever is greater) at the time of informed consent Has morphologically documented primary AML or AML secondary to myelodysplastic syndrome (MDS) or other myeloproliferative

2018 Clinical Trials

212. Supportive Care Service Availability for Cancer Caregivers in Community Oncology Practices

of phase II/III and phase III trials to https://nctn-data-archive.nci.nih.gov/. This will become the primary means for sharing raw data, and we will adhere to the guidelines spelled out in the NCTN/NCORP Data Archive Usage Guide. De-identified data from studies not covered by the agreement (e.g., phase II and observational studies) will be made available upon request. All data files will be de-identified. De-identification procedures will meet the HIPAA criteria as detailed in the Code of Federal

2018 Clinical Trials

213. Medication Adherence Clinical Decision Support

or health educators. Pharmacists will follow a script template for the phone outreach that walks them through the IMB intervention and data collection. Currently, pharmacists at the three participating chains (Goodrich, Park Nicollet and HealthPartners) have full read/write access to the EMR in full compliance with Health Insurance Portability and Accountability Act (HIPAA) regulations. They can make medication changes and/or communicate with the prescriber through secure messaging or phone consultation

2018 Clinical Trials

214. GrafixPL PRIME Evaluation Case Study

such as medications, tobacco, nutrition, comorbidities, diabetes control, infection, perfusion, and activity. Wound healing, including wound size and adverse events will be evaluated. The objective of this study is to understand the use of this product to evaluate wound healing in 40 patients. Condition or disease Intervention/treatment Phase Diabetic Foot Ulcer Biological: GrafixPL PRIME Phase 4 Detailed Description: Screening and Enrollment: Review and sign the Informed Consent and HIPAA Authorization Review

2018 Clinical Trials

215. Study of Pediatric Migraine: The Pediatric Migraine Registry

Method: Non-Probability Sample Study Population Participants aged 4-17 years old (inclusive) diagnosed with migraine with or without aura will be eligible for participation in this study. Criteria Inclusion Criteria: 4 to 17 years of age inclusive at the time of enrollment visit Meets International Classification of Headache Disorders, 3rd edition criteria for migraine with or without aura Guardian provides informed consent/HIPAA Participant provides assent if developmentally appropriate and required

2018 Clinical Trials

216. Simulation RCT of Telemedical Support for Paramedics

resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Telemedicine The telemedicine arm will have 2-way audiovisual connection with a pediatric medical control physician. Other: Telemedicine The mobile, HIPAA-compliant, video-conferencing platform, Zoom Pro, will be used on tablet computers as a low-cost telemedicine platform for the intervention group. This platform uses Wi-Fi or cellular data connection for video streaming. The investigators will use the telephone

2018 Clinical Trials

217. Trial of Atezolizumab Plus Chemotherapy After Progression on Single Agent PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. Age ≥ 18 years at the time of consent. ECOG Performance Status of 0-2 within 28 days prior to registration. Histological or cytological confirmed metastatic or unresectable locally advanced urothelial carcinoma (primary tumor: renal pelvis

2018 Clinical Trials

218. Adherence to Inpatient Venous Thromboembolism Prophylaxis: A Single Institution's Concurrent Review. (Abstract)

, utilizing a cloud-based, HIPAA-compliant tool, on a convenience sample of hospitalized patients. Adherence and agreement between different assessment modalities were calculated. Seventy-six patients consented for participation. Nurse documented adherence was 66% (29/44), 44% (27/61), and 89% (50/56) for mechanical, ambulatory, and chemoprophylactic prophylaxis, respectively. Patient report and nurse documentation showed moderate agreement for mechanical and no agreement for ambulatory adherence (κ

2018 American Journal of Medical Quality

219. Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone

into a research database. All patients, or their legal guardians, must sign a written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization in accordance with institutional guidelines. Exclusion Criteria: Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals. Patients with significant drug or other allergies or autoimmune diseases may be enrolled at the Investigator?s discretion. Patients who require monitored

2018 Clinical Trials

220. Automated Navigation to Improve Outpatient Colonoscopy Adherence

an automated text message navigation intervention using the Way to Health (WTH) platform to improve patient engagement prior to colonoscopy completion. The WTH platform is a Penn Medicine platform that is hosted on site at the University of Pennsylvania. The platform allows custom text messages to automatically be sent to patients, in addition to bidirectional message capabilities. WTH is protected by a secure firewall and is a HIPAA compliant platform. In the past year, our team conducted a quality

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>